Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bevacizumab added to standard induction chemotherapy in older AML patients
2006-001777-19Phase 2Active
- Sponsor
- HOVON
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab in acute myeloid leukemia (AML), sponsored by HOVON. Primary endpoint: Incidence of dose-limiting toxicities (DLT). Started Aug 2006; status: active.
02
Drugs
bevacizumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2006-001777-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001777-19.